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Substance Use Disorder and Prescription Drug Monitoring Programs: Preventing 
Discrimination Through Monitoring Technology 
 
Antony B. Kamel 
 
PART I: INTRODUCTION 
 
Although Substance Use Disorder (“SUD”) is a medically recognized disease1, popular 
stigma still views it as a choice.  This causes patients suffering from SUD to deal with negative 
implications in their daily lives.  Federal legislation, such as 42 C.F.R. § 22  (“Part 2”) provide 
essential privacy protections to these patients—ensuring treatment records are not disclosed 
without the patient’s consent.  These protections are essential because anti-discriminatory laws, 
such as the Americans With Disabilities Act3 (“ADA”), fail to protect patients suffering from 
SUD.  Recently, lobbying efforts to amend Part 2 have gained traction.  Supporters of amending 
Part 2 claim that it hinders medical providers from providing collaborative care.  
This comment will analyze Part 2, discuss the protections it provides, and lastly, assert that 
these protections must remain in place.  It will offer solutions to mitigate the concerns of medical 
providers who claim Part 2 hinders the delivery of collaborated care.  
Part II of this note will give a brief history of SUD, its recognition as a medical disease, the 
stigma surrounding it, and the legal and practical consequences of such stigma.  Part III will 
detail the protections provided by Part 2.  Part IV will analyze the failure of anti-discriminatory 
laws to protect patients suffering from SUD.  Part V will summarize the arguments posed by 
those in favor of amending Part 2.  Part VI will discuss Prescription Drug Monitoring Programs 
(“PDMPs”) and their role in monitoring prescription drug use.  Part VII, incorporating the use of 
 
 
1 Mayo Clinic, Diseases and Conditions; available at https://www.mayoclinic.org/diseases-conditions/drug-
addiction/symptoms-causes/syc-20365112. 
2 42 U.S.C. 290dd-2. 
3 42 U.S.C. § 12101-12117. 
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PDMPs, proposes a solution to protect the privacy of SUD patients while also addressing the 
concerns of medical providers who support amending Part 2.  Namely, this comment proposes 
that State PDMP programs should expand access to SUD providers and mandate frequent and 
consistent checks of the PDMP.  This comment aims to highlight the negative implications 
patients suffering from SUD face, address the arguments posed by proponents of removing Part 
2’s protections, and provide a solution to mitigate these concerns while still maintaining the 
essential protections of Part 2.   
PART II: ILLNESS AND STIGMA 
 SUD is a disease effecting millions of Americans4.  A majority of medical professionals 
agree that SUD is an illness, rather than a choice made by the patient5.  Despite such medical 
findings, negative stigma towards SUD and its victims is still very prevalent6.  The ramifications 
of this stigma result in practical, legal, and medical consequences for patients.  
SUD GENERALLY 
 
 SUD effects a large number of Americans; in 2017, an estimated 19.7 million Americans 
suffered from substance use disorder.7  SUD is a disease that affects a person’s brain and 
behavior, leading to an inability to control the use of a legal or illegal drug, substance, or 
medication.8  The term “drugs” encompasses prescription drugs, such as prescription opioid 
painkillers, alcohol, marijuana, and nicotine.9  SUD is recognized as a primary, progressive, 
 
 
4 Substance Abuse and Mental Health Services Administration (SAMHSA), 2017 NSDUH Annual National Report, 
(2018); available at https://www.samhsa.gov/data/report/2017-nsduh-annual-national-report. 
5 Mental Health America supra note 4; see also American Psychiatric Association, Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5), available at https://www.psychiatry.org/psychiatrists/practice/dsm. 
6 SAMHSA supra note 4.  
7 Id.   
8 Mayo Clinic supra note 1.  
9 Id. (explaining that non-illegal substances such as alcohol and nicotine are considered “drugs”).  
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chronic, relapsing and treatable disease10, caused by both environmental factors and genetics.11  
Medical professionals have consistently found that SUD “remolds” the brain’s chemistry, 
causing patients to ignore health concerns, work obligations, and family.12  Medical research has 
also suggested that certain individuals are predisposed to SUD.13  Contrary to popular belief, the 
medical community is in agreement that SUD does not stem from a decision made by the patient, 
but is rather a medical condition14.  SUD is also often accompanied with mental health 
disorder.15 Of the roughly 20 million16 Americans suffering from SUD, 41.2 percent also 
suffered from a mental health disorder.17  It is evident that SUD is an epidemic in America that 
requires extreme care from by the healthcare system.18 
STIGMA SURROUNDING SUD 
 Stigma is defined as “a set of negative beliefs that a group or society holds about a topic 
or group of people.”19 Although, as mentioned above, SUD is recognized in the medical 
community as a chronic medical disease, studies show that many people view it as a moral 
failing and perceive patients negatively.20  Public stigma regarding SUD patients is very 
 
 
10 Mental Health America, Position Statement 33: Substance Use Disorders; available at 
https://www.mhanational.org/issues/position-statement-33-substance-use-disorders (explaining that SUD is a 
disease). 
11 Mayo Clinic supra note 1 (finding that SUD is caused by both environmental factors and genetics).  
12 Mental Health America supra note 6; see also American Psychiatric Association, Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5), available at https://www.psychiatry.org/psychiatrists/practice/dsm. 
13 Moffit, Arseneault, Belsky, et al: A gradient of childhood self-control predicts health, wealth, and public safety, 
Proc Nat’l Acad. Sci. USA, 2693, 2698, 2011; available at https://www.pnas.org/content/pnas/108/7/2693.full.pdf.  
14 Id.  
15 Supra note 6.  
16 Supra note 4.  
17 Supra note 7. 
18 Mental Health America, Position Statement 33: Substance Use Disorders; available at 
https://www.mhanational.org/issues/position-statement-33-substance-use-disorders (explaining the harsh reality of 
SUD in America and the need to address the issue from a healthcare collaborative approach).  
19 Lauren Villa, Shaming The Sick: Addiction and Stigma, DrugAbuse.com, 
https://drugabuse.com/addiction/stigma/. 
20 Colleen L. Barry, Emma Elizabeth McGinty, Bernice Pescosolido, Howard H. Goldman, Stigma, Discrimination, 
Treatment Effectiveness and Policy Support: Comparing Public Views about Drug Addiction with Mental Illness, 
Psychiatr. Serv. 2014 Oct; 65(10): 1269–1272. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285770/. 
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prevailing and has real-word consequences.21  Such stigma and discrimination causes legal and 
practical ramifications. Many times, the patient being treated for SUD treatment, not the actual 
use of an illegal substance, was the reason patients were discriminated against.22  For example, 
parents have been denied visiting rights to their children even when they were in recovery and 
not actively engaged in drug use.23  Patients were evicted from shelters because they were being 
treated for opioid addiction.24   
Stigma surounding SUD patients also effects public housing eligibility.25  A study by the 
U.S. Department of Housing and Urban Development found that almost all Public Housing 
Authorities (“PHAs”) enforce bans against individuals with history of alcohol or drug use far 
more stringent than required by federal law.26  PHAs also used a great deal of discretion in 
determining housing rights of such individuals.27  Because of the negative stigma towards SUD 
patients, these discretionary decisions by PHAs have resulted in negative consequences for 
patients.28 
Besides having practical and real world ramifications, fear of judgement and implications 
from others both deters patients from entering treatment and results in poor treatment.29  A Dutch 
university conducted a study evaluating health professionals’ attitudes towards patients with 
SUD and the ramifications of these attitudes on the healthcare delivery system in Western 
 
 
21 See, K. Lopez, D. Reid “Discrimination Against Patients With Substance Use Disorders Remains Prevalent And 
Harmful: The Case For 42 CFR Part 2” Health Affairs, April 13, 2017, available at  
https://www.healthaffairs.org/do/10.1377/hblog20170413.059618/full/  (citing examples of stigma consequences 
effecting patients). 
22 Id.  
23 Id. 
24 Id.  
25 Marah A. Curtis et. al, Alcohol, Drug, and Criminal History Restrictions in Public Housing; 
https://www.huduser.gov/portal/periodicals/cityscpe/vol15num3/ch2.pdf  
26 Id. 
27 Id.  
28 Id. 
29 Villa supra note 15.  
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countries.30  This study found that health professionals had a negative attitude towards patients 
suffering from SUD and entered the treatment of those individuals with stigma and bias.31  Those 
professionals “perceived violence, manipulation, and poor motivation as impeding factors in the 
healthcare delivery for these patients.”32  The study also found that negative attitudes from 
professionals had a negative impact on patients’ comfort in the healthcare process.33  Similarly, a  
British study interviewed a mix of patients suffering from SUD and treating registered nurses.34  
The study found that the two most prevalent issues in the nurse-SUD patient relationship were 
“lack of knowledge to care” and “distrust and detachment”.35  The study also found that nurses 
pre-judged their SUD patients, and as a result, patients were disconnected with their care 
providers increasing conflict, disruption, and violence.36 
 It is evident that SUD is a prevalent disease in America and stigma surrounding it 
negatively impacts patients.  The current stigma causes SUD patients to be discriminated against 
both legally and procedurally in matters such as custody of children and housing rights.  Stigma 
further discourages SUD from seeking treatment and disadvantages them in the healthcare 
delivery process.  The negative implications of SUD stigma are real and pervasive. 
Part III: PROTECTING SUD PATIENTS THROUGH 42 C.F.R.§ 2 
 
 
30 van Boekel, Brouwers, van Weeghel, Garretson, Stigma among health professionals towards patients with 
substance use disorders and its consequences for healthcare delivery: systematic review, Drug Alcohol 
Depend. 2013 Jul 1;131(1-2):23-35; https://www.ncbi.nlm.nih.gov/pubmed/23490450.  
31 Id. 
32 Id. 
33 Id. (“Negative attitudes of health professionals diminished patients' feelings of empowerment and subsequent 
treatment outcome.”) 
34 Monks, R., Topping, A., & Newell, R. The dissonant care management of illicit drug users in medical wards, the 
views of nurses and patients: A grounded theory study. Journal of advanced nursing, 69(4), 935-946 (2013), 
(https://www.ncbi.nlm.nih.gov/pubmed/22776007) . 
35 Id. 
36 Id.  
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 42 C.F.R. § 2, better known as Part 2 was enacted in 1987 and is codified in 42 U.S.C. 
290dd-2.37  Part 2 was enacted by Congress to respond to the fear that stigma would dissuade 
individuals from seeking SUD treatment.38  Specifically, the legislative history of Part 2 cites a 
fear of SUD records being negatively used against patients.39  The regulations are also aimed at 
ensuring that a patient who is seeking treatment for SUD is not made more vulnerable due to the 
risk of treatment records being disseminated.40  The Department of Health and Human Services, 
in the Federal Register, has acknowledged that disclosure of SUD records may lead to a variety 
of negative consequences for the patient.41   
Part 2 creates an extra layer of protection for patients, providing for a limited set of 
circumstances where a patient’s treatment record may be disclosed without such patient's 
knowledge.42  In sum, Part 2 applies to any “federally assisted… individual or entity (other than 
a general medical facility) who holds itself out as providing, and provides, substance use disorder 
diagnosis, treatment, or referral for treatment.”4344  It requires that the records, identity, 
diagnosis, or treatment records of any patient which are kept as part of a substance abuse 
 
 
37 42 U.S.C. 290dd-2. 
38 Susan Awad, Confused by Confidentiality? A Primer on 42 CFR Part 2, American Society of Addiction 
Medicine, https://www.asam.org/resources/publications/magazine/read/article/2013/08/15/confused-by-
confidentiality-a-primer-on-42-cfr-part-2  
39 Confidentiality of Substance Use Disorder Patient Records, 82 Fed. R. 6052, 6053 (Jan 18, 2017). Federal 




41 Id. (disclosure may lead to “[l]oss of employment, loss of housing, loss of child custody, discrimination by 
medical professionals and insures, arrest, prosecution, and incarceration).  
42 Id. 
43 42 C.F.R. §2.11 
44 “Most drug and alcohol treatment programs are federally assisted.  For-profit programs and private practitioners 
that do not receive federal assistance of any kind would not be subject to the requirements of [Part 2] unless the 
State licensing or certification agency requires them to comply.  However, any clinician who uses a controlled 
substance for detoxification or maintenance treatment of [SUD] requires a federal DEA registration and becomes 
subject to [Part 2] through th[at] DEA license.” Awad supra note 34.  
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treatment or rehabilitation program be kept confidential, except for a few circumstances.45  
Besides the exceptions46, the only way qualified SUD treatment records may be disclosed to any 
party is through prior written consent of the patient.4748   
PART IV: FAILURE OF ANTI-DISCRIMINATORY LEGISLATION TO PROTECT 
SUD PATIENTS 
 Current federal legislation, such as the Americans With Disabilities Act49 (“ADA”), fails 
to protect patients suffering from SUD from the consequences of negative stigma surrounding 
their disease50.  The ADA does not protect individuals engaged in current illegal drug use. 51 This 
prevents patients suffering from SUD from being protected by anti-discriminatory laws available 
to other Americans, causing these patients to suffer severe consequences.  
THE ADA GENERALLY 
 The ADA, enacted in 1990, is a civil rights law which prohibits the discrimination against 
individuals suffering from disabilities.52  The ADA mandates that qualified individuals be 
protected from discrimination in employment, education, transportation, and all public and 
private places which are accessible by the general public.53  The goal of the ADA is to ensure 
that American’s with disabilities are ensured the same rights and access as those without 
 
 
45 42 U.S.C. 290dd-2(a). 
46 42 U.S.C. 290dd-2(b)(2)(A)-(C) (listing the following exceptions; (i) during a medical emergency, (ii) to qualified 
personnel for scientific research provided that identities remain confidential, and (iii) and if authorized by court 
order).  
47 42 U.S.C. 290-dd-2(b)(1).  
48 It is important to note the contrast of Part 2 to the Health Insurance Portability and Accountability Act 
(“HIPAA”), which allows a health care provider to alert family or law enforcement of illegal drug use.  See 
generally 45 C.F.R. § 164.512(j).  
49 42 U.S.C. § 12101-12117. 
50 See Nielsen v. Moroni Feed Co., 162 F.3d 604, 611 n.12 (the ACA did not protect an employee who was 
discharged for addiction stemming from prescription drugs).  
51 42 U.S.C. § 12114 (under the ADA individuals “currently engaging in the illegal use of drugs” are not covered). 
52 ADA National Network, What is The Americans With Disabilities Act (ADA)?, https://adata.org/learn-about-ada. 
53 Id.  
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disabilities.54  The ADA provides protections to individuals on the basis of disability similar to 
the constitutional protections afforded to individuals on the basis of race, sex, age, and religion.55  
The ADA, however, treats individuals suffering from SUD using illicit substances, different than 
individuals suffering from other medical diseases.56  Under the ADA, an individual who is 
currently engaging in the illegal use of drugs is not classified as an “individual with a 
disability”.57   
DEFINING “CURRENT ILLEGAL DRUG USE” UNDER THE ADA 
“Illegal use”, as defined by the ADA, encompasses more than just the use of “street 
drugs”.  It also encompasses the use of prescription drugs.58   
Because only individuals who are “currently” using illegal drugs are excluded from ADA 
protection59, defining the use of “current” is essential.  The Equal Opportunity Commission 
("EEOC") has defined “current” to mean that an individual had used a drug “recently enough” to 
justify an employer believing that the employee’s use is an ongoing problem.60  The EEOC has 
further explained that “[current drug use] is not limited to the day of use, or recent weeks or 
days, in terms of an employment action.”.61  The EEOC further notes that an employee who tests 





56 Sharing the Dream: Is the ADA Accommodating All? Chapter 4: Substance Abuse under the ADA, United States 
Commission on Civil Rights, https://www.usccr.gov/pubs/ada/ch4.htm.  
57 42 U.S.C. § 12114(a). 
58 See Nielsen v. Moroni Feed Co., 162 F.3d 604, 611 n.12 (10th Cir. 1998) (“[there] is no doubt that, under the 
ADA, illegal drug use includes the illegal misuse of pain-killing drugs… as well as illegal street drugs like 
cocaine”.).  
59 42 U.S.C. § 12114(a). 
60 See 29 C.F.R. § 1630.3.  
61 Equal Employment Opportunity Commission, Technical Assistance Manual on the Employment Provisions (Title 
I) of the Americans with Disabilities Act, §8.2, https://askjan.org/publications/ada-specific/Technical-Assistance-
Manual-for-Title-I-of-the-ADA.cfm#spy-scroll-heading-74. 
62 Id. (“An applicant or employee who tests positive for an illegal drug cannot immediately enter a drug 
rehabilitation program and seek to avoid the possibility of discipline or termination by claiming that s/he now is in 
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Although courts have not set a firm timeline in defining “current”, multiple courts have 
discussed the meaning of a “current” use under the ADA.63  In Zenor v. El Paso Healthcare 
Systems, Ltd.64, an employee was discharged five weeks after he had used cocaine.65  The court 
determined that because he had used cocaine five weeks prior to his discharge, he was not 
entitled to ADA protection.66   
Employees who assert that they are in a drug rehabilitation treatment program can still be 
considered “current” users.67  In Salley v. Circuit City Stores, Inc.68,  the employee had a long 
history of addiction to heroin, but was drug-free for 10 years.69  The employee suffered a relapse 
and sought treatment.70  After the employer took action against the employee, the court analyzed 
whether the employee was protected by the ADA.71  In holding that he was not, the court noted 
that a three week period since last use was entirely too short to make the employees use not 
“current”.72  In Shafer v. Preston Memorial Hospital Corp.73, the court assessed the meaning of 
“current” under the ADA when an employee was addicted to prescription medication.74  The 
employee then entered rehabilitation.75  After she completed rehabilitation, she was discharged.76  
 
 
rehabilitation and is no longer using drugs illegally. A person who tests positive for illegal use of drugs is not 
entitled to the protection that may be available to former users who have been or are in rehabilitation.”.) 
63 See Zenor v. El Paso Healthcare Systems, Ltd., 176 F.3d 847 (5th Cir. 1999) (defining “current” illegal drug use 
when an issue arose whether drug use five weeks prior was “current”); see, e.g., Salley v. Circuit City Stores, Inc., 
160 F.3d 977 (3d Cir. 1998); Shafer v. Preston Memorial Hospital Corp., 107 F.3d 274 (4th Cir. 1997).  
64 Zenor, 176 F.3d 847 (5th Cir. 1999). 
65 Id. at 852. 
66 Id. at 867.  
67 See Salley, 160 F.3d 977 (3d Cir. 1998); Shafer, 107 F.3d 274 (4th Cir. 1997); Collings v. Longview Fibre Co., 63 
F.3d 828 (9th Cir. 1996).  
68 Salley, 160 F.3d 977 (3d Cir. 1998).  
69 Id. at 978. 
70 Id. at 979.  
71 Id. 
72 Id. at 980 (“[there is] no case in which a three-week period of abstinence has been considered long enough to take 
an employee out of the status of ‘current’ user.”).  
73 Shafer., 107 F.3d 274. 




In finding that the employee was a “current” user, the court noted that someone is a “current” 
user if drugs had been used “in a periodic fashion during the weeks and months prior to 
discharge.”77  In Collings v. Longview Fibre Co.78, several employees were fired for illegal drug 
use, although they had completed a rehabilitation program.79  These employees even took drug 
tests to show that they were not using when they were fired.80  Despite this, in finding that the 
employees were not protected by the ADA, the court held that “current” use did not mean “on 
the day of, or within a matter of days or weeks before,” but meant the use of drugs “recently 
enough to indicate the individual actively engaged in such conduct.”81  Although courts have not 
consistently defined “current” under the ADA, it is clear that employees suffering from SUD 
may be unprotected by the ADA, even when they have not used drugs for months or have 
completed rehabilitation.  
EMPLOYER’S DEFENSE OF A “DIRECT THREAT” 
 The ADA allows employers to require that employees do not “pose a direct threat to the 
health or safety of other individuals in the workplace.”82  A “direct threat” is defined as “a 
significant risk to the health or safety of others that cannot be eliminated by reasonable 
accommodation.”83  This provision may be used by an employer to “deny a job or benefit to an 
individual with a disability.”84  Generally, under the ADA, when determining if a disabled 
employee poses a direct threat, the analysis focuses on whether the employee has the capacity to 
 
 
77 Id. at 278 (““the ordinary or natural meaning of the phrase ‘currently using drugs’ does not require that a drug 
user have a heroin syringe in his arm or a marijuana bong to his mouth at the exact moment contemplated… [rather 
someone is “current” if drugs were used] in a periodic fashion during the weeks and months prior to discharge.”). 
78 Collings, 63 F.3d 828 (9th Cir. 1998). 
79 Id. at 830.  
80 Id. at 833.  
81 Id.  
82 42 U.S.C. § 12113(b).  
83 42 U.S.C. § 12111(3). 
84 42 U.S.C. § 12113(a).  
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safely perform their job.85  In making this determination the “factors to be considered include: 
(1) [t]he duration of the risk; (2) [t]he nature and severity of the potential harm; (3) [t]he 
likelihood that the potential harm will occur; and (4) [t]he imminence of the potential harm.”86  
The EEOC has noted that an employer may not discriminate against an employee just because of 
a slight increased risk, rather, the risk must be substantial.87   
Although the EEOC has attempted to define a “direct threat”, courts have also been 
forced to analyze its meaning under the ADA.88  In EEOC v. Exxon Corp.,89 the District Court 
analyzed the “direct threat” and its effect on an ADA discrimination claim.90  In that case, the 
EEOC attempted to enforce the remedies of the ADA on behalf of numerous employees.91  The 
employees were Exxon employees who had been working as engineers and had subsequently 
been demoted to mechanics when their history of drug and alcohol abuse were discovered.92  
One employee had abused prescription medication when he was 19, subsequently entered 
rehabilitation and joined Exxon when he was in his 40s.93  Another employee had entered 
rehabilitation for alcoholism before joining Exxon and had never experienced a relapse while at 
Exxon.94   
In the suit, the EEOC alleged that Exxon’s policy, which prevented employees who had 
undergone some sort of SUD treatment but were employed in “safety-sensitive designated 
 
 
85 29 C.F.R. § 1630.2(r).  
86 Id.  
87 Supra note 56 at § 8.7 (“[an employer may not deny benefits or employment] merely because of a slightly 
increased risk.  The risk can only be considered when it poses a significant risk, i.e., high probability of substantial 
harm; a speculative or remote risk is insufficient.”).  
88 See EEOC v. Exxon Corp., 967 F.Supp. 208 (N.D. Tex. 1997); reversed 203 F.3d 871 (5th Cir. 2000).  
89 Id. 
90 Id.  
91 Id. at 209.  
92 Id. at 210-11.  
93 Id. 
94 Exxon, 967 F.Supp at 210-11.  
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positions” was in violation of the ADA.95  The EEOC argued that the blanketed policy 
discriminating against all individuals who had a history of SUD violated the ADA because it did 
not utilize the ADA safety factors.96  Exxon argued that the ADA does not mandate such an 
individualized assessment.97  Exxon further asserted that “that the risk of relapse of any 
rehabilitated substance abuser is too great for certain types of jobs such that individual 
assessment is futile.”98  The District Court, in rejecting the EEOC and employees’ claims held 
that the ADA contains an exception to the individualized factors required.99  The District Court 
emphasized the need for protecting employers from the risks created by patients who had 
undergone SUD treatment.100  The District Court also pointed to other discrimination statues that 
allow blanketed exclusions from certain positions when safety is at issue.101   
On appeal, the EEOC argued that employers must meet the “direct threat” defense, 
codified in 42 U.S.C. § 12113(b)102.103  The 5th Circuit held that although the ADA’s “direct 
threat” defense is an individual analysis, the “business necessity”104 defense allows for an across-
the-board blanketed policy.105  Using the analysis, the Court held that an employer may use the 
 
 
95 Id.  
96 Id.; supra note 81 (listing the factors an employer must consider).  
97 Exxon, 867 F.Supp. at 211.  
98 Id. at 210.  
99 Id. at 213.  
100 Id. at 212 (“[A]s courts define the scope of the ADA's coverage of employees who have illegally used drugs, they 
underscore the need to protect employers from the risks posed by recently rehabilitated employees.”).  
101 Id. (“The Rehabilitation Act, the Age Discrimination in Employment Act ("ADEA"), and Title VII also provide 
guidance because these statutes are similar in purpose to the ADA and have often been relied upon in interpreting 
the ADA.”). 
102 42 U.S.C. § 12113(b). 
103 EEOC v. Exxon Corp., 203 F.3d 871, 873 (5th Cir. 2000) (“With regard to safety sensitive requirements that 
screen out or tend to screen out an individual with a disability or a class of individuals with disabilities, an employer 
must demonstrate that the requirement, as applied to the individual, satisfies the “direct threat” standard . . . in order 
to show that the requirement is job-related and consistent with a business necessity.”).  
104 42 U.S.C. § 12113(a). 
105 EEOC, 203 F.3d at 874 (“While no court has as yet addressed the question we answer today, several trends in 
ADA case law indicate that the direct threat test is not deployed where an employer uses a general safety-based 
qualification standard applicable across-the-board.”).  
 14 
“business necessity” defense, without conducting an individual analysis as to each employee, to 
enact an across-the-board policy, effectively discriminating against SUD patients who had no 
relapses during their employment.106 
In sum, the ADA allows employers to require that an employee does not pose a “direct 
threat” to the workplace.  Normally, this analysis considers each individual employee.  However, 
when employers use the “business necessity” defense in conjunction with the “direct threat” 
defense, courts have allowed employers to utilize blanketed catch-all guidelines without 
considering the needs of individual employees.  These company-wide sweeping guidelines have 
resulted in policies personally effecting patients who had been treated for SUD and have not 
relapsed. 
PART V: LOBBYING EFFORTS TO AMMEND 42 C.F.R.§ 2 
 Recently, many groups, specifically health care providers have argued that Part 2 must be 
amended.107  Proponents of amending Part 2 offer 3 arguments to support amending.108  These 
arguments are: (i) Part 2 is outdated and not aligned with HIPAA109, preventing the efficient 
sharing of medical records between providers110; (ii) Part 2 perpetuates stigma against SUD 
patients by treating SUD records differently from other diseases111; and (iii) Part 2 increases 
costs for healthcare providers112  This comment will dissect each argument in turn.  
 
 
106 Id. at 875 (“We have found nothing in the statutory language, legislative history or case law that persuades that 
the direct threat provision addresses safety-based qualification standards in cases where an employer has developed 
a standard applicable to all employees of a given class.”). 
107 See Sarah E. Wakeman, Peter Friedmann “Outdated Privacy Law Limits Effect Substance Use Disorder 
Treatment: The Case Against 42 CFR Part 2” Health Affairs, March 1, 2017, available at  
https://www.healthaffairs.org/do/10.1377/hblog20170301.058969/full/ (arguing for the amending of Part 2); supra 
note 35 at 6057-6061 (summarizing public feedback to potential amendments of Part 2).  
108 Wakeman, et. al supra note 102; supra note 35.  
109 42 U.S.C. §1320d-6. 
110 Wakeman, et. al supra note 102.  
111 Id.  
112 Supra note 35 at 6058.  
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THE ARGUMENT THAT PART 2 IS OUTDATED 
 One argument posed by proponents of amending Part 2 is that the added layer of 
protection provided by Part 2 hinders efficient medical care.113  These proponents also argue that, 
because Part 2 was enacted before HIPAA, these regulations are no longer needed.114  
Specifically, proponents argue that in the present age of patients being treated for SUD in a 
primary care setting, Part 2 prevents providers from utilizing electronic health records, and 
exchanging information.115  Other proponents, believing that SUD should be treated in the 
broader general medical care setting, argue that Part 2 hinders the facilitation of electronic 
exchange of SUD records which results in patients receiving sub-par care.116  Believing that 
patients should be treated for SUD in a general healthcare setting, some argue that Part 2 should 
be amended to allow all healthcare providers to see SUD treatment records.117  Apart from 
arguing that SUD patients should be treated in the general healthcare setting, some argue that 
Part 2 maintains barriers impeding the sharing of information needed for coordinated care, even 
if SUD is not treated in a general healthcare setting.118  Supports of amending Part 2 argue that 
these barriers may result in providers being unaware of a patient’s medical history.119 In terms of 
HIPAA, supporters of amending Part 2 point to the fact that Part 2 was enacted before HIPAA, 
 
 
113 Id. (“Designed to protect stigmatized patients, ironically this added layer of protection now creates virtual care 
silos, hinders good medical care…in the contemporary era of electronic health records (EHRs), health information 
exchanges, behavioral health integration, and HIPAA privacy protections.”). 
114 Wakeman, et. al supra note 102 (“The intentions of 42 CFR part 2 were good and necessary in the era before the 
Health Insurance Portability and Accountability Act of 1996 (HIPAA).”).  
115 Supra note 35 at 6057.  
116 Id. at 6058 (supporting the “facilitation of electronic exchange of [SUD] treatment” because separate restrictions 
“ultimately negatively impacts patients and the care they receive[.]”. 
117 Id. (arguing that “[SUD records] should be accessible to all healthcare facilities for the sole purpose of better 
treating … patients.”).  
118 Id. (Part 2 creates “barriers and create additional barriers that impede the sharing of information exchange and 
care coordination[.]”). 
119 Id. at 6057 (“the current practice of keeping [SUD records] separate from [other records] … could contribute to 
providers missing critical information needed for treating patients.”). 
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and these protections are no longer needed.120  They assert that, because Part 2 is no longer 
needed due to HIPAA, Part 2 should be aligned with HIPAA, maintaining privacy while 
providing efficient care.121 
THE ARGUMENT THAT PART 2 PERPETUATES STIGMA 
Another argument made in support of amending Part 2 is that the added privacy 
protections mandated by Part 2 perpetuate stigma.122  This argument assumes that, because 
legislation treats certain records “differently”, the legislature is sending the message that these 
records are secret and shameful.123  Separating SUD from other records is hypocritical, argue 
supporters of amending Part 2.124  The reasoning is as follows: by safeguarding these records, we 
are sending a message that SUD is not just like any other disease.125  Asserting that SUD records 
should be treated like any other records, some argue that this added stigma ultimately impacts the 
type of care SUD patients receive.126 
 
 
120 Wakeman, et. al supra note 102 (“The intentions of 42 CFR part 2 were good and necessary in the era before the 
Health Insurance Portability and Accountability Act of 1996 (HIPAA).”).  
121 Supra note 35 at 6060 (“[A]ligning [Part 2} with HIPAA would help to strike an appropriate balance between 
protecting sensitive health information while providing coordinated care.”); Id. (“[Aligning Part 2 with HIPAA 
would] broaden the allowable sharing of data for purposes of .. patient safety.”).  The arguments for the purpose of 
patient safety assert that without integrated care, a doctor, unaware of a patient’s SUD may accidently prescribe an 
opioid when doing so would not be appropriate.  Wakeman, et. al supra note 102 (“ Imagine the harm that occurs 
when a patient with opioid use disorder goes to see a physician who is not able to see that patient's diagnosis due to 
42 CFR part 2, and unknowingly prescribes opioids.”).  
122 Id. (“[Part 2’s] added layer of protection … perpetuates stigma[.]”); see also id at 6057 (“Some …asserted that 
maintaining a separate set of confidentiality restrictions aimed solely at [SUD] providers and patients perpetuates the 
discrimination associated with [SUD][.]”.  
123 Wakerman, et. al supra note 102 (“Requiring additional releases perpetuates stigma by sending the message that 
these are secret, shameful conditions that must be treated differently from any other disease.”).  
124 Id. ("The message is also hypocritical: physicians and patients are told addiction is a disease like any other, but 
also that this disease requires a level of secrecy higher than diabetes, cancer, or HIV.”).  
125 Id.  
126 Supra note 35 at 6058 (“maintaining a separate set of confidentiality restrictions aimed solely at substance use 
disorder providers and patients perpetuates the stigma associated with substance use disorder and ultimately 
negatively impacts patients and the care they receive, suggesting that issues of substance use disorder information 
confidentiality should be part of the broader general medical care confidentiality regulations.”).  
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THE ARGUMENT THAT PART 2 IMPOSES EXTRA COSTS ON HEALTHCARE 
PROVIDERS 
 The last argument posed in support of amending Part 2 is that its added restrictions result 
in added costs to healthcare providers.127  Because Part 2 mandates that SUD records are kept 
separate from ordinary medical records, hospitals are required to maintain separate log-ins to 
access both types of records.128  Essentially, some argue that the burden of added administrative 
costs of separating SUD from other records outweighs any benefits created by Part 2.129  
Proponents of amending Part 2 use the added costs that Part 2 imposes on providers to justify the 
proposition that facilities are less likely to implement SUD programs.130  Finding that SUD 
patients are “the highest cost utilizers in the health care system”, supporters of amending Part 2 
also assert that the added protections created by Part 2 are particularly costly on the healthcare 
system.131  In sum, advocates of amending Part 2 believe that because Part 2 adds costs on 
healthcare providers, it should be amended to align with other privacy laws, allowing for easier 
access and compliance for providers.  
 Multiple arguments are advanced by supporters of removing Part 2’s added privacy 
protections.132  Among these arguments are: (i) Part 2 is outdated and SUD records should be 
 
 
127 Id. (“[Part 2] maintain[s]… high compliance costs [on providers].”).  
128 Wakerman, et. al supra note 102 (“At many hospitals, the EHR systems require a separate log-in to access 
records sequestered under 42 CFR part 2. These additional administrative burdens are hardly a selling point to new 
clinicians at a time when we need more physicians willing to care for patients with addiction.”).  
129 Id.  
130 Supra note 35 at 6058 (“[P]art 2 regulations keep the [SUD] treatment system isolated from general health care 
providers and reduce access to [SUD] treatment being added by general health care organizations, which due to 
administrative burden and liability fears, are less likely to add [SUD] treatment.”); see id. (“[P]art 2 regulations have 
unintended consequences, including… the burdens associated with constantly updating expiring consents.”).  
131 Id. (“[T]he burdens caused by [Part 2] are particularly costly because patients with [SUD] are among the highest 
cost utilizers in the healthcare system.”).  
132 See id. (arguing that Part is outdated); see also id. at 6060 (arguing that Part 2 perpetuates stigma); see also id. at 
6058 (arguing that Part 2 imposes significant costs on the healthcare system).  
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treated like any other treatment records133; (ii) by separating SUD records from others and 
requiring consent for disclosure134, Part 2 perpetuates stigma; and (iii) Part 2 imposes significant 
costs on the healthcare system which outweigh any benefits created.135   
 
PART VI: MONITORING TECHNOLOGY: PRESCRIPTION DRUG MONITORING 
PROGRAMS 
 PDMPs are state enacted monitoring systems aimed at preventing the illicit overuse of 
prescription drugs.136  First, this comment will explain PDMPs generally, then it will explain 
current access to PDMPs by providers, then it will analyze current use of PDMPs by SUD 
treatment providers specifically.  
PDMPS GENERALLY 
 PDMPs are tools employed by healthcare providers and law enforcement to reduce 
prescription drug abuse, misuse, and diversion.137  PDMPs record a patient’s prescription record 
by collecting and monitoring data electronically submitted by prescribers and dispensers  of 
prescription drugs.138  The data is managed by each state and used by a variety of entities to: (i) 
educate about prescription drug abuse; (ii) research prescription drug abuse; (iii) enforce action 
against abusers or diverters; and (iv) prevent abuse.139  PDMPs can only be accessed by entities 
 
 
133 Supra note 103. 
134 Supra note 117. 
135 Supra note 122.  
136 PDMP Frequently Asked Questions FAQs), Prescription Drug Monitoring Program Training and Technical 
Assistance Center (PDMP TTAC); https://www.pdmpassist.org/pdf/PDMP_FAQs.pdf.  
137 Id.; see also Prescription Drug Monitoring Programs: A Guide For Healthcare Providers, Substance Abuse and 
Mental Health Services Administration (SAMHSA), https://store.samhsa.gov/system/files/sma16-4997.pdf 
(describing PDMPs, their background, and funding sources).  
138 PDMP TTAC supra note 131.  
139 Id. (“The data are used to support states’ efforts in education, research, enforcement, and abuse prevention. 
PDMPs are managed under the auspices of a state, district, commonwealth, or territory of the United States.”).  
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authorized by law.140  In recent years, however PDMPs have served another serious function – 
they allow prescribers the ability to get a complete picture of their patients in order to make a 
more informed healthcare decision.141 
 Presently, all states including Washington D.C., Guam, and Puerto Rico have functioning 
PDMPs.142  These PDMPs are administered by a variety of agencies including: (i) consumer 
protection agencies; (ii) substance abuse agencies; (iii) professional licensing boards; (iv) law 
enforcement entities; (v) departments of health; and (vi) boards of pharmacy143  Of the various 
agencies administering the programs, pharmacy boards administer the majority.144  Each state 
monitors drugs according to applicable federal and state controlled substances laws.145  For 
example, 11 states monitor drugs scheduled II-IV, while 40 states Guam and Puerto Rico 
monitor drugs scheduled II-V.146  Generally, PDMPs are updated on a daily or weekly basis, 
adding information about patients and prescribing.147  This, however, is changing.  Recently 
states have implemented real time (emphasis added) reporting, allowing prescriptions to appear 
on the PDMP within 5 minutes of dispensing.148 Although the state requirements vary regarding 
 
 
140 Id. (“PDMPs do not interfere with appropriate medical use. [] Prescription data is provided only to entities 
authorized by state law.”); id. (“PDMPs do not infringe on the legitimate prescribing of a controlled substance by a 
practitioner acting in good faith and in the course of a professional practice.”).  
141 Opioid abuse in th U.S. and HHS actions to address opioid-drug related overdoses and death, U.S. Department 
of Health and Human Services, https://aspe.hhs.gov/basic-report/opioid-abuse-us-and%20-hhs-actions-address-
opioid-drug-related-overdoses-and-deaths (“Advances in technology have enabled PDMPs to take on another 
important role— that of an adjunct source of information that prescribers and pharmacists can use to improve the 
care and safety of individual patients. Helping healthcare providers make the most informed prescribing and 
dispensing decisions, as part of an initiative to address opioid-related overdoses and deaths, is a federal government 
priority.”).  




146 Id. (containing a chart showing the breakdown of states monitoring various drugs).  
147 SAMHSA supra note 132 (“Most PDMPs update their data on a daily or weekly basis, enabling prescribers and 
dispensers to assess a patient’s recent patterns of use or misuse.”).  
148 Id. (“Oklahoma became the first state to institute real-time reporting, with prescription data available within 5 
minutes after medication is dispensed.”) (internal citations omitted).  
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when a prescriber or dispenser must check the PDMP149, the CDC suggests that both prescribers 
and dispensers check the PDMP at least once every three months and prior to every opioid 
prescription150 in order to monitor prescribing habits and patient safety.  Although PDMPs 
throughout the nation are updated and checked in accordance with state laws and do not adhere 
to a uniform federal policy, PDMPs can be utilized by both prescribers and dispensers to monitor 
illicit drug use, sometimes within minutes.  Thus, PDMPs play an important role in the detection 
and monitoring of drugs being improperly used.  
CURRENT REGULATIONS GOVERNING PRESCRIBERS’ USE OF PDMPS 
 As mentioned above, different state laws regulate who can access PDMPs and their 
records.151  Certain states may allow professionals such as nurse practitioners and physician 
assistants as well as doctors and pharmacists to access the PDMP.152  This broad access is meant 
so that various professionals can review a patient’s record from a PDMP to confirm their 
prescription history and ensure that drugs are being used properly.153  
In terms of the type of reports available to prescribers, regulations vary by state.154  For 
example, 30 states allow prescribing professionals to see their: (i) patient’s prescription history; 
 
 
149 PDMP Mandatory Query by Prescribers and Dispensers, Prescription Drug Monitoring Program Training and 
Technical Assistance Center (PDMP TTAC), https://www.pdmpassist.org/pdf/Mandatory_Query_20190827.pdf 
(presenting a map demonstrating the requirements of each state).  
150 Checking the PDMP: An Important Step to Improving Opioid Prescribing Habits, Center for Disease Control; 
https://www.cdc.gov/drugoverdose/pdf/pdmp_factsheet-a.pdf (“State requirements vary, but the CDC recommends 
checking at least once every 3 months and consider checking prior to every opioid prescription.”).  
151 SAMHSA supra note 132 (“Depending on the particular state law, the types of professionals who may register to 
access PDMP records [varies].”).  
152 Id. 
153 Id. (“To ensure that the patient does not misuse prescribed medication, the practitioner can monitor PDMP 
data[.]”).  
154 See PDMP Reports Available to Prescribers, PDMP TTAC, 
https://www.pdmpassist.org/pdf/Reports_to_Prescribers_20190816.pdf (showing different types of reports 
dispensed by each state’s PDMP).  
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(ii) their own prescribing history; and (iii) query audit trail155.156  20 states allow access to only 
the patient’s prescription history and their own prescribing history.157  One state allows 
prescribers to see patient history and a query audit trail only, while two states allow access to 
only patient history reports.158  Although states vary in terms of access to content, all PDMPs 
across the nation allow prescribers to view a patient’s history, ensuring that patient safety is 
always maintained.  
There are also differences in state laws regarding how frequently and by which method a 
healthcare professional receives and is required to check PDMP reports.159  Presently, 19 states 
require both prescribers and dispensers to check the PDMP when prescribing or dispensing a 
covered drug.160  27 states only require prescribers to check the PDMP in these instances, not 
dispensers.161  7 states, however, do not require any PDMP check for qualified drugs.162  In these 
situations, the PDMP is simply a resource for the prescriber and dispenser, not a mandatory step 
in the prescription process.  In terms of how prescribers receive reports from the PDMP, there 
are two distinct scenarios.163  16 states send PDMP reports to prescribers only when the 
 
 
155 A query audit trail is a system that allows a healthcare professional to see who accessed their records and for 
what reason. PDMP Delegate Account Systems, PDMP Center of Excellence, Brandeis University, 
https://www.pdmpassist.org/pdf/PDMP_admin/Briefing%20on%20Delegate%20Account%20Systems.pdf.  
156 PDMP TTAC supra note 148.  
157 Id.  
158 Id.  
159 See PDMP Mandatory Query by Prescribers and Dispenser, PDMP TTAC, 
https://www.pdmpassist.org/pdf/Mandatory_Query_20190827.pdf (showing differences between states in requiring 
mandatory PDMP checks); see also Engaged in Sending Solicited and Unsolicited Reports to Prescribers, TTAC, 
https://www.pdmpassist.org/pdf/Prescribers_Sol_Unsol_Reports_20190816.pdf, (showing differences between 
states sending reports to prescribers).  
160 PDMP TTAC supra note 144.  
161 Id.  
162 Id.  
163 PDMP TTAC supra note 154 (showing differences in receiving PDMP reports).  
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prescriber requests such material, whereas 37 states send PDMP reports to prescribers both when 
they request the reports and randomly when not requested.164 
Differences exist among: (i) who can access PDMPs; (ii) the types of reports available to 
those who have access to the PDMPs; and (iii) the frequency and method of receiving such 
reports.  Even though these differences exist, the goals of PDMPs remains the same: to allow 
both prescribers and dispensers of covered drugs to confirm a patient’s prescription history and 
to ensure that prescriptions are used properly165.  
USE OF PDMP DATA BY SUD TREATERS 
Patients being treated for SUD are often treated in one of two settings; opioid treatment 
programs (“OTPs”) and office-based opioid treatment programs (OBOTs).166  Both programs 
allow patients access to medication such as methadone and naloxone.167  Because only OTPs are 
covered by Part 2, a provider in an OTP setting who prescribed methadone is prohibited from 
reporting the prescription to the PDMP.168  On the other hand, OBOT’s must disclose medication 
to the PDMP.169  Only OTPs are relevant to this comment.  Because OTPs do not disclose 
prescriptions to the PDMP, theses prescribers must monitor their patients to ensure safety.170   
Presently, 14 states allow SUD treatment programs to access the PDMP.171  Some states 
require that OTPs query the PDMP as soon as the patient arrives at the facility.172  It should be 
 
 
164 Id.  
165 SAMSHA supra note 137.  
166 Use of PDMP Data by Opioid Addiction Treatment Programs, PDMP Center of Excellence, Brandeis University, 
https://www.pdmpassist.org/pdf/Resources/Use%20of%20PDMP%20data%20by%20opioid%20treatment%20progr
ams.pdf.  
167 Id. (“OTPs and OBOTs provide treatment that ensures access to the most appropriate FDA-approved 
medications.”).  
168 Id.  
169 Id. 
170 Id. (“it is critical for patient safety and MAT effectiveness for programs to monitor their patients’ use.”); Id. 
(noting the potential harms of methadone treatment).  
171 Id.  
172 Id. (internal citations omitted).  
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noted that PDMP queries by SUD providers do not reveal their status to outside 
providers.173Although there are no set guidelines for PDMP use by providers, the American 
Association for Treatment of Opioid Dependence ("AATOD") recommends that providers who 
have access to PDMPs utilize them in treating patients.174  Individual providers have enacted 
practices utilizing PDMPs to better protect their patients’ interests.175  In Washington, for 
example, providers check the PDMP as soon as the patient arrives and at least once every six 
months to detect improper drug use.176  Providers also query the PDMP whenever: (i) a patient is 
considered for take-home medication; (ii) the patient exhibits signs of impairment; (iii) the 
patient exhibits a change in behavior, or (iv) tests positive for a controlled substance.177  These 
policies, although not mandated by law, have yielded substantial results.  In Delaware, providers, 
by querying the PDMP frequently, discovered that patients were selling prescribed medication or 
using them recreationally.178   
Although PDMPs may serve as important resources to SUD providers, some have 
complained about their integration into practice.  Some providers found that the PDMPs were 
non-intuitive and lacked integration with other health records.179  Providers also suggested that 
support-staff should be granted access to the PDMP and allow a provider the ability to look up 
 
 
173 Id.  
174 Guidance to OTPs Concerning the Use of Prescription Monitoring Program (PMP) Databases, American 
Association for the Treatment of Opioid Dependence, http://www.aatod.org/policies/policy-statements/guidance-to-
otps-concerning-the-use-of-prescription-monitoring-program-pmp-databases/.  
175 See generally PDMP Center of Excellence, Brandeis University supra note 160 (explaining the practices 
employed in North Carolina, Washington, Delaware, Vermont, and Massachusetts).  
176 Id. (“[The staff is required to] query the PDMP at admission and at least every six months during the first year of 
treatment, then as part of the annual medical exam; PDMP reports are placed in the patient’s file.”).  
177 Id.  
178 Id. (“Some clients appeared to be doing well in treatment were discovered, with the help of the PDMP, to be 
selling prescribed controlled substances or using them non-medically.”).  
179 Id.  
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all patients at once.180  Folks engaging in PDMP checks also noted that some PDMPs did not 
provide for real-time patient updates, sometimes lagging behind by days or weeks.181 
 Although PDMPs have certain restrictions, it is clear that increased usage of PDMPs by 
SUD providers may reap a number of benefits including revealing improper drug use.  Providers 
who have access to PDMPs, involved in a close relationship with the patient, are in a position to 
monitor, identify, and remedy any potential abuse of drugs monitored by the PDMP.  
PART VII: ANALYSIS: UTILIZING PDMPS TO ENSURE SUD PATIENT SAFETY 
AND CONFIDENTIALITY  
State PDMP programs should consider expanding access to SUD providers and mandate 
frequent and consistent checks by these providers.  By checking the PDMP frequently, SUD 
providers will ensure that patients are not prescribed dangerous substances when they should not 
be, filling in any potential gaps created by Part 2. 
As discussed above, there have been many arguments advanced in support of amending 
Part 2.  Among these are: (i) Part 2 is outdated and prevents providers from seeing a patient’s full 
medical history and may lead to overprescribing; (ii) Part 2 perpetuates stigma by separating 
SUD records from other records; and (iii) Part 2 imposes excessive costs on healthcare providers.  
By incorporating the use of PDMPs by SUD providers, these issues can be remedied, creating a 
solution that focuses on patient safety while still maintaining Part 2 privacy. 
Expanding PDMP access to providers who are treating patients for SUD and mandating 
their use will ensure that patients are not overprescribed medication and remain safe.  SUD 
providers are in a position of trust with SUD patients.  By allowing these providers to access the 
 
 
180 Id.  
181 Id.  
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PDMP, they will be able to check what their patients are being prescribed.  Providers will be able 
to detect indiscriminate providing in two ways.  First, these providers will detect improper 
prescribing by their mandatory query of PDMP.  For example, imagine a patient who is being 
treated for SUD.  The patient is likely to go to a doctor, who, because of Part 2 is unaware of the 
patient’s SUD history, and that doctor may prescribe opioids which could be detrimental to the 
patient’s health.  However, the SUD provider, by querying the PDMP will be able to detect the 
opioid prescription, discuss it with the patient, and make a more informed decision.  This will 
ensure that patient is safe without having the non-SUD provider see any SUD record.  Second, 
SUD providers will be able to query the PDMP whenever they suspect suspicious behaviors or 
activity from their patients, thus uncovering and preventing any potential misuse.  When a SUD 
provider has access to the PDMP, they will be able to ensure their patients are not being 
described dangerous drugs when they detect something unusual.  The proposed solution ensures 
that no over-prescribing occurs and that the drugs used by patients are consistently monitored.  
Part 2’s privacy protections are essential and should not be removed.  The argument that 
Part 2, by separating SUD records from others, perpetuates stigma is wholly incorrect.  As 
mentioned above, not only are there stigma issues surrounding SUD, but real-life implications.  
Patients are discriminated against in terms of housing rights, parental rights, and denied any 
protection from anti-discriminatory laws.  Separating the documents, protects from stigma, not 
perpetuates it.  This comment is filled with examples of patients who have not used drugs in 
months or even years, and are still discriminated against due to stigma.  If these records were 
accessible by any employer or doctor, the results would be devastating for patients.   
Patient privacy should never be compromised in favor of administrative ease.  People 
who believe that Part 2 must be amended frequently cite the added costs it creates.  By separating 
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records, providers are forced to use separate channels to check a patient’s records.  Although Part 
2 does imposes costs on providers, the benefits it provides severely outweigh those costs.  As 
mentioned, Part 2 allows patients to control who sees their medical records, protecting their 
privacy.  This added benefit should never be compromised just because a provider will be 
required to spend a few extra minutes with each patient.  
CONCLUSION 
It is clear that SUD is a medical condition effecting millions of Americans annually.  
Although medical research has shown that SUD is a medical condition, there exists negative 
stigma surrounding SUD.  People may view it as a moral failing or choice and reserve opinions 
about patients who suffer from it.  The results from this negative stigma can be harmful.  Patients 
suffering from SUD face consequences such as loss of housing and loss of parental rights, even 
when they had not actively used any illegal drugs.  Not only are SUD patients impacted legally 
and logistically, but they are judged by healthcare providers who treat for reasons other than 
SUD.  
 In order to confront and reduce some of the negative impacts of SUD stigma, Congress 
enacted 42 C.F.R. Part 2.  Part 2 provides essential protection to SUD patients, allowing them the 
ability to decide who sees their medical records.  Part 2 is also important because it is the only 
federal legislation which protects SUD patients from the stigma surrounding their disease.  As 
mentioned above, the ADA, a major anti-discriminatory law, fails to protect patients with SUD 
and would allow employers and landlords to treat individuals differently because they suffer 
from SUD, even when they are not using any drugs.  
Part 2 is not all positive, however.  It comes with some serious flaws.  Part 2, keeping 
SUD documents separate from ordinary documents, may reduce the ability for non-SUD 
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providers to see what a patient is prescribed and lead to improper prescribing.  It is also argued 
that by separating documents, Part 2 perpetuates stigma and increases costs on providers.  
  A solution, which allows providers to monitor their patients, however, exists.  By 
expanding PDMP access to SUD providers and mandating their use, states can find a solution 
that would ensure providers monitor the PDMP frequently enough to detect indiscriminate 
prescribing, while still keeping SUD records out of hands of those who do not need to see them, 
preventing negative impacts of stigma. This solution will serve to both protect patient’s health 
and privacy.  Patient privacy, however, must never been compromised for the sake easing the 
administrative tasks of providers.  The stakes are entirely too high.  
 
